A Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-552 in Participants With Mild Alzheimer's Disease
Latest Information Update: 05 Apr 2025
At a glance
- Drugs ABBV 552 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors AbbVie
- 24 Oct 2024 Status changed from active, no longer recruiting to completed.
- 12 Jun 2024 Planned primary completion date changed from 6 Aug 2024 to 14 Aug 2024.
- 06 Jun 2024 Status changed from recruiting to active, no longer recruiting.